| Authors: |
Nayak L; Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Grommes C; Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Psoinos C; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Reu FJ; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Takazawa A; Clinical Development, ONO Pharmaceutical Co, Ltd, Osaka, Japan., Uttarwar M; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Xia B; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Carvajal LA; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Kim S; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Sherman ML; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Batchelor TT; Neurology, Brigham and Women's Hospital, Boston, MA, USA. |
